Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical

Experienced leadership team to build on established commercial platform and accelerate Lifeward's ne

Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimat

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst conse

Revenue increase and operating performance improve as capital-efficient distribution strategy gains

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LF

The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’

Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , brin

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restor

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan

Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation m

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate

Oramed  strategic transaction successfully closed and $10 million financing received Oratech acquisi

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFW

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past si

Lifeward Ltd. (NASDAQ: LFWD - Get Free Report) shares were up 2.5% on Thursday. The stock traded as

Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innova

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(2.85) per share which missed the analyst conse

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath t

Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability

Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innov

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasd

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and

Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and

Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innov

Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal E

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Bu

Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in inno

Lifeward (NASDAQ:LFWD) affirms FY2025 sales outlook from $24.000 million-$26.000 million to $24.000

Lifeward (NASDAQ:LFWD) reported quarterly losses of $(0.19) per share which beat the analyst consens